• Bayer's darolutamide with ADT and radiation therapy reduced metastasis or death risk in prostate cancer patients at high recurrence risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.